Bezafibrate and simvastatin: Different Beneficial effects for different therapeutic aims [2] (multiple letters)

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 4, 2004, Pages 1978-1979

  Tenenbaum, Alexander ^a   Fisman, Enrique Z ^a   Motro, Michael ^a   Desideri, Giovambattista ^b   Ferri, Claudio ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; ENDOTHELIUM CELL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LETTER; LIPID PEROXIDATION; MORBIDITY; MORTALITY; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 1942440458     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-032038     Document Type: Letter

References (0)